Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fariel LaMountain

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Health Affairs Scholar|July 29, 2024
Biosimilar underutilization alone does not foretell a broken biologics marketFariel LaMountain, Molly T Beinfeld, William Wong, et al.
Health Affairs (Project Hope)|September 3, 2024
US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices DecreaseMolly T Beinfeld, Fariel LaMountain, William Wong, et al.
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
Health Affairs Scholar|December 1, 2025
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savingsMolly T Beinfeld, Priyanka Ghule, Fariel LaMountain, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Health Affairs Scholar|July 29, 2024
Biosimilar underutilization alone does not foretell a broken biologics marketFariel LaMountain, Molly T Beinfeld, William Wong, et al.
Health Affairs (Project Hope)|September 3, 2024
US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices DecreaseMolly T Beinfeld, Fariel LaMountain, William Wong, et al.
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
Health Affairs Scholar|December 1, 2025
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savingsMolly T Beinfeld, Priyanka Ghule, Fariel LaMountain, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
Pageof 1